UY26360A1 - Agonistas del receptor 3 (r3) del peptido activador de adenilato ciclasa (pacap) de la petuitaria y sus métodos de uso farmacológico. - Google Patents

Agonistas del receptor 3 (r3) del peptido activador de adenilato ciclasa (pacap) de la petuitaria y sus métodos de uso farmacológico.

Info

Publication number
UY26360A1
UY26360A1 UY26360A UY26360A UY26360A1 UY 26360 A1 UY26360 A1 UY 26360A1 UY 26360 A UY26360 A UY 26360A UY 26360 A UY26360 A UY 26360A UY 26360 A1 UY26360 A1 UY 26360A1
Authority
UY
Uruguay
Prior art keywords
petuitaria
agenists
pacap
receptor
methods
Prior art date
Application number
UY26360A
Other languages
English (en)
Inventor
Clark Pan
Manami Tsutsumi
Armen Shanafelt
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of UY26360A1 publication Critical patent/UY26360A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Esta invención presenta novedosos péptidos que funcionan in vivo estimulando la liberación de insulina de las células beta pancreáticas en forma dependiente de la glucosa. Estos péptidos secretagogos de insulina estimulan la liberación de insulina en las células de islotes de ratas in vitro e in vivo.
UY26360A 1999-09-28 2000-09-28 Agonistas del receptor 3 (r3) del peptido activador de adenilato ciclasa (pacap) de la petuitaria y sus métodos de uso farmacológico. UY26360A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40783299A 1999-09-28 1999-09-28
US59528000A 2000-06-15 2000-06-15

Publications (1)

Publication Number Publication Date
UY26360A1 true UY26360A1 (es) 2001-04-30

Family

ID=27020026

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26360A UY26360A1 (es) 1999-09-28 2000-09-28 Agonistas del receptor 3 (r3) del peptido activador de adenilato ciclasa (pacap) de la petuitaria y sus métodos de uso farmacológico.

Country Status (19)

Country Link
EP (1) EP1192182B1 (es)
AT (1) ATE397625T1 (es)
AU (1) AU7726600A (es)
CA (1) CA2379604A1 (es)
CO (1) CO5280048A1 (es)
CZ (1) CZ296858B6 (es)
DE (1) DE60039111D1 (es)
DO (1) DOP2000000071A (es)
ES (1) ES2307534T3 (es)
GT (1) GT200000162A (es)
HU (1) HUP0202175A3 (es)
MY (1) MY131983A (es)
PE (1) PE20010612A1 (es)
RU (1) RU2269354C2 (es)
SK (1) SK5552002A3 (es)
SV (1) SV2002000184A (es)
TW (1) TWI264438B (es)
UY (1) UY26360A1 (es)
WO (1) WO2001023420A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
CA2472956A1 (en) * 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
EP1583550A2 (en) * 2003-01-16 2005-10-12 D. Collen Research Foundation vzw Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
PT2644206T (pt) 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
EP1713493A4 (en) * 2004-01-27 2009-06-24 Bayer Pharmaceuticals Corp PEPTIDE-RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND PHARMACOLOGICAL METHODS OF USING THESE AGONISTS
WO2005113594A1 (en) * 2004-05-21 2005-12-01 Eli Lilly And Company Selective vpac2 receptor peptide agonists
ES2302201T3 (es) * 2004-05-21 2008-07-01 Eli Lilly And Company Agonistas peptidicos del receptor vpac2 selectivos.
EP1768686A4 (en) * 2004-06-12 2007-11-14 Bayer Pharmaceuticals Corp PEGYLATION OF VASOACTIVE INTESTINAL PEPTIDE (VIP) / HYPOPHYDE-ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) RECEPTOR 2 (VPAC2) AGONISTS AND METHOD OF USE
EP1781695A1 (en) * 2004-08-18 2007-05-09 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US7595294B2 (en) * 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
MX2007004116A (es) * 2004-10-08 2007-10-05 Forbes Medi Tech Res Inc Composiciones farmaceuticas de polipeptidos intestinales vasoactivos.
ATE528005T1 (de) 2005-01-10 2011-10-15 Cortendo Ab Publ 2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen
WO2006121588A2 (en) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
WO2007021498A1 (en) * 2005-08-11 2007-02-22 Eli Lilly And Company Selective vpac2 receptor peptide agonists
JP2009519212A (ja) 2005-10-26 2009-05-14 イーライ リリー アンド カンパニー 選択的ｖｐａｃ２受容体ペプチドアゴニスト
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
TW200745163A (en) * 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
CA2664800A1 (en) 2006-10-02 2008-04-10 Timothy Andrew Stewart Ketoconazole enantiomer in humans
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
AU2009264242A1 (en) 2008-06-27 2009-12-30 Novartis Ag Organic compounds
EP2358200A4 (en) 2008-11-17 2012-05-16 Merck Sharp & Dohme BICYCLIC AMINES SUBSTITUTED FOR THE TREATMENT OF DIABETES
JP2012522748A (ja) 2009-04-01 2012-09-27 ノバルティス アーゲー ステアロイル−ｃｏａデサチュラーゼ調節用スピロ誘導体
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011039358A1 (en) 2009-10-01 2011-04-07 Novartis Ag Pyrazole derivatives which modulate stearoyl-coa desaturase
CA2779088A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
CA2784799C (en) 2009-12-30 2014-06-10 Shanghai Fochon Pharmaceutical Co Ltd Certain dipeptidyl peptidase inhibtors
CU24075B1 (es) * 2011-08-26 2015-01-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.
CN104411710A (zh) 2012-04-16 2015-03-11 卡内克制药公司 作为ptp-1b抑制剂前体的稠合的芳族膦酸酯衍生物
WO2015023890A1 (en) * 2013-08-14 2015-02-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
JP6523328B2 (ja) 2014-04-17 2019-05-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． タンニン酸シタグリプチン複合体
JP6924148B2 (ja) 2015-04-16 2021-08-25 ハー・ルンドベック・アクチエゼルスカベット 抗ｐａｃａｐ抗体及びそれらの使用
SG11201808630WA (en) 2016-04-15 2018-10-30 Alder Biopharmaceuticals Inc Humanized anti-pacap antibodies and uses thereof
WO2020074958A1 (en) 2018-10-12 2020-04-16 Strongbridge Dublin Limited Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2077764C (en) * 1990-03-17 2002-12-10 Nobuhiro Suzuki Antibody to pacap and use thereof
AU656230B2 (en) * 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
CA2196308C (en) * 1995-06-09 2000-10-17 Kazuhisa Kashimoto Peptide, bronchodilator and blood flow ameliorant
WO1998002453A2 (en) * 1996-07-15 1998-01-22 Universite Libre De Bruxelles Peptidic ligands having a higher selectivity for the vip1 receptor than for the vip2 receptor
FR2775902B1 (fr) * 1998-03-13 2001-05-11 Assist Publ Hopitaux De Paris Utilisation d'analogues du vip dans la prevention et le traitement des lesions cerebrales du nouveau-ne humain
CZ2001253A3 (cs) * 1998-07-20 2001-11-14 Societe De Conseils De Recherches Et D'application Peptidové analogy PACAP

Also Published As

Publication number Publication date
SK5552002A3 (en) 2003-05-02
DOP2000000071A (es) 2002-02-28
ES2307534T3 (es) 2008-12-01
RU2269354C2 (ru) 2006-02-10
EP1192182B1 (en) 2008-06-04
WO2001023420A2 (en) 2001-04-05
CZ20021085A3 (cs) 2003-01-15
CZ296858B6 (cs) 2006-07-12
HUP0202175A2 (en) 2002-10-28
WO2001023420A3 (en) 2001-08-30
MY131983A (en) 2007-09-28
GT200000162A (es) 2002-03-22
DE60039111D1 (de) 2008-07-17
EP1192182A2 (en) 2002-04-03
PE20010612A1 (es) 2001-07-12
HUP0202175A3 (en) 2005-01-28
CA2379604A1 (en) 2001-04-05
CO5280048A1 (es) 2003-05-30
TWI264438B (en) 2006-10-21
SV2002000184A (es) 2002-06-07
ATE397625T1 (de) 2008-06-15
AU7726600A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
UY26360A1 (es) Agonistas del receptor 3 (r3) del peptido activador de adenilato ciclasa (pacap) de la petuitaria y sus métodos de uso farmacológico.
ECSP024346A (es) Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
HUP0004394A2 (hu) Egyláncú bifunkcionális glikoprotein hormonok
SV1998000122A (es) Medicamentos ref. pu 3375/sv
PL336759A1 (en) Controllable release of drugs administered by holding them beneath the tongue or behind the bucca
DK1171465T3 (da) Analoger til gastroinhibitorisk peptid og deres anvendelse til behandling af diabetes
DE69826005D1 (de) Gerät zur steigerung der glukoseproduktion durch stimulation pankreatischer beta-zellen
UY27893A1 (es) Agonistas del receptor (vpac2) del peptido activante de la adenilatociclasa hipofisaria (pacap) y sus metodos de uso farmacologicos
DK0693924T4 (da) Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil
EE05584B1 (et) Glkokortikoidretseptori modulaatorid
ES2165211T3 (es) Jeringa de inyeccion que incluye un dispositivo para la preparacion de la inyeccion.
EP1034188A4 (en) METHOD FOR DESIGNING ANGONISTS AND IGF RECEPTOR ANTAGONISTS
EP1027054A4 (en) LOCAL CONTRIBUTION OF PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION
HUP0002311A2 (hu) Ergolinszármazékok és szomatosztatin receptorként való alkalmazásuk
ATE419268T1 (de) Haemasterlin analoge
DOP2006000106A (es) Agonistas del receptor (vpac2) de péptido activador de adelinato ciclasa hipofisaria (pacap), y sus métodos de uso farmacológico
Rehfeld et al. Naming progastrin-derived peptides
WO2001042287A3 (en) Putative human g-protein coupled receptors
ECSP003683A (es) Agonistas del receptor 3(r3) del peptido activador de la adenilato ciclasa de la pituitaria y sus metodos de uso farmacologico
AR025902A1 (es) Agonistas del receptor 3 (r3) del peptido activador de la adenilato ciclasa de la pituitaria y sus metodos de uso farmacologico
BG103859A (en) The use of 1-ar(alk)yl-imidazolin-2-on for the treatment of fear and stress conditions
WO2002044381A8 (en) Human vno receptor (r1)
Julien et al. A rapid survey of the literature indicates that most of the studies performed on isolated islets from rat, mice, or human pancreas dealt with culture conditions and secretion of the different hormones
SE9701916D0 (sv) Method of finding synthetic peptides derived from the melanocortin-1 receptor (MC1R) that can stimulate MHC class irestricted CTL's that recognize naturally processed peptides of MC1R on abnormal cells including e. g. human melanomas
ES2122940A1 (es) Soporte para el telefono movil.

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20111129